The 2023-2028 Outlook for Antioxidants in Japan
This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all cities in Japan). This study gives, however, Professor Parker's estimates for the latent demand, or potential industry earnings (P.I.E.), for antioxidants in Japan. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of Japan. For each region, he also shows his estimates of how the P.I.E. grows over time. In order to make th...
11/28/2022 | Japan Outlook 2023
The 2023-2028 Outlook for Anti-Obesity Drugs in Japan
This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all cities in Japan). This study gives, however, Professor Parker's estimates for the latent demand, or potential industry earnings (P.I.E.), for anti-obesity drugs in Japan. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of Japan. For each region, he also shows his estimates of how the P.I.E. grows over time. In order to m...
11/28/2022 | Japan Outlook 2023
The 2023-2028 Outlook for Anti-Money Laundering Software in Japan
This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all cities in Japan). This study gives, however, Professor Parker's estimates for the latent demand, or potential industry earnings (P.I.E.), for anti-money laundering software in Japan. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of Japan. For each region, he also shows his estimates of how the P.I.E. grows over time. I...
11/28/2022 | Japan Outlook 2023
The 2023-2028 Outlook for Anti-Migraine Drugs in Japan
This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all cities in Japan). This study gives, however, Professor Parker's estimates for the latent demand, or potential industry earnings (P.I.E.), for anti-migraine drugs in Japan. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of Japan. For each region, he also shows his estimates of how the P.I.E. grows over time. In order to ...
11/28/2022 | Japan Outlook 2023
The 2023-2028 Outlook for Antimicrobial Susceptibility Testing in Japan
This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all cities in Japan). This study gives, however, Professor Parker's estimates for the latent demand, or potential industry earnings (P.I.E.), for antimicrobial susceptibility testing in Japan. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of Japan. For each region, he also shows his estimates of how the P.I.E. grows over t...
11/28/2022 | Japan Outlook 2023
The 2023-2028 Outlook for Anti-Malarial Drugs in Japan
This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all cities in Japan). This study gives, however, Professor Parker's estimates for the latent demand, or potential industry earnings (P.I.E.), for anti-malarial drugs in Japan. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of Japan. For each region, he also shows his estimates of how the P.I.E. grows over time. In order to ...
11/28/2022 | Japan Outlook 2023
The 2023-2028 Outlook for Anti-Itching Skin Treatments in Japan
This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all cities in Japan). This study gives, however, Professor Parker's estimates for the latent demand, or potential industry earnings (P.I.E.), for anti-itching skin treatments in Japan. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of Japan. For each region, he also shows his estimates of how the P.I.E. grows over time. In ...
11/28/2022 | Japan Outlook 2023
The 2023-2028 Outlook for Anti-Inflammatory Therapeutics in Japan
This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all cities in Japan). This study gives, however, Professor Parker's estimates for the latent demand, or potential industry earnings (P.I.E.), for anti-inflammatory therapeutics in Japan. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of Japan. For each region, he also shows his estimates of how the P.I.E. grows over time. I...
11/28/2022 | Japan Outlook 2023
The 2023-2028 Outlook for Anti-Inflammatory Scleroderma Drugs in Japan
This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all cities in Japan). This study gives, however, Professor Parker's estimates for the latent demand, or potential industry earnings (P.I.E.), for anti-inflammatory scleroderma drugs in Japan. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of Japan. For each region, he also shows his estimates of how the P.I.E. grows over ti...
11/28/2022 | Japan Outlook 2023
The 2023-2028 Outlook for Anti-Inflammatory Lupus Drugs in Japan
This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all cities in Japan). This study gives, however, Professor Parker's estimates for the latent demand, or potential industry earnings (P.I.E.), for anti-inflammatory Lupus drugs in Japan. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of Japan. For each region, he also shows his estimates of how the P.I.E. grows over time. In...
11/28/2022 | Japan Outlook 2023
